Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
Quality of life
[44] Systematic review	1529 people 5 RCTs in this analysis	Improvement in the fatigue component of the Chronic Respiratory Disease Questionnaire (CRQ) 85 days of treatment with ipratropium with short-acting beta2 agonists Absolute results not reported	WMD 0.13 95% CI 0.02 to 0.23 P = 0.02	Effect size not calculated	ipratropium
[44] Systematic review	1529 people 5 RCTs in this analysis	Improvement in the emotion component of the CRQ 85 days of treatment with ipratropium with short-acting beta2 agonists Absolute results not reported	WMD 0.17 95% CI 0.05 to 0.29 P = 0.006	Effect size not calculated	ipratropium
[44] Systematic review	1529 people 5 RCTs in this analysis	Improvement in the mastery component of the CRQ 85 days of treatment with ipratropium with short-acting beta2 agonists Absolute results not reported	WMD 0.18 95% CI 0.06 to 0.30 P = 0.004	Effect size not calculated	ipratropium